[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions (North America, Europe, Asia Pacific, Rest of the World) – Global Forecast up to 2025

August 2019 | 140 pages | ID: T4E2FFDBF47DEN
Infoholic Research

US$ 4,000.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025

This market research report includes a detailed segmentation of the global TNF alpha inhibitors market by drug class (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab), pipeline analysis (phase I, phase II, and phase III), and regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global TNF Alpha Inhibitors Market Research:

Infoholic’s market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019–2025. TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF).

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019–2025.

Key players operating in this field, i.e., AbbVie Inc., Amgen Inc., Johnson & Johnson, and Celgene Corporation, are generating the majority of the revenue in the global TNF alpha inhibitors market.

According to Infoholic Research analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

By Drug Class:
  • Adalimumab
  • Certolizumab Pegol
  • Etanercept
  • Golimumab
  • Infliximab
In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019–2025.

Pipeline Analysis:
  • Phase I
  • Phase II
  • Phase III
Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.

By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Based on geography, North America dominated the market in 2018 with a market share of over 60% and is expected to maintain this position during the forecast period. Europe is projected to grow at a high CAGR during the forecast period. The increasing acceptance of biosimilars and increasing investments in the R&D of new drugs make Europe the fastest-growing region during the forecast period.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019–2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.

Key Vendors:
  • AbbVie Inc.
  • Novartis AG
  • Amgen Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • Celltrion Healthcare
  • Samsung Bioepis Co. Ltd.
  • Apogenix
  • 3SBIO Inc.
  • Shanghai CP Guojian Pharmaceutical Co. Ltd.
Key Competitive Facts:
  • UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study “Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT)”.
  • Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
  • In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.
Benefits – The report provides complete details about the sub-segment of the global TNF alpha inhibitors market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the pharmaceuticals segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:
  • Understanding the potential market opportunity with precise market size and forecast data.
  • Detailed market analysis focusing on the growth of TNF alpha inhibitors industry.
  • Factors influencing the growth of the TNF alpha inhibitors market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the TNF alpha inhibitors industry in both developed and developing regions.
  • Key insights related to major segments of the TNF alpha inhibitors market.
  • Latest market trend analysis impacting the buying behavior of the consumers.
1 INDUSTRY OUTLOOK

1.1 Industry Overview
  1.1.1 Global Driver for Pharmaceutical Demand
  1.1.2 R&D Pipeline in Pharmaceutical Industry
  1.1.3 Top Pharma Drugs by Sales ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
1.4 Trends of the Immunotherapy Drugs Market

2 REPORT OUTLINE

2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 MARKET SNAPSHOT

3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the TNF Alpha Inhibitors Market
3.4 Related Markets
  3.4.1 Oncology Drugs
  3.4.2 Biologics
  3.4.3 Biosimilars

4 MARKET OUTLOOK

4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics
  5.1.1 Drivers
    5.1.1.1 Increasing prevalence of chronic autoimmune disease
    5.1.1.2 Constant research to develop target-based biologics
  5.1.2 Opportunities
    5.1.2.1 Continuous development of biosimilars
    5.1.2.2 Increasing opportunities in the emerging market
  5.1.3 Restraints
    5.1.3.1 Complex drug development process
    5.1.3.2 Patent expiry
5.2 DRO – Impact Analysis
5.3 Key Stakeholders

6 PRODUCT: MARKET SIZE AND ANALYSIS

6.1 Overview
6.2 Adalimumab
6.3 Certolizumab Pegol
6.4 Etanercept
6.5 Golimumab
6.6 Infliximab

7 PIPELINE ANALYSIS: MARKET SIZE AND ANALYSIS

7.1 Overview
7.2 Phase I
7.3 Phase II
7.4 Phase III

8 REGIONS: MARKET SIZE AND ANALYSIS

8.1 Overview
8.2 North America
  8.2.1 Overview
  8.2.2 US
  8.2.3 Canada and Others
8.3 Europe
  8.3.1 Overview
  8.3.2 UK
  8.3.3 Germany
  8.3.4 Russia and Ukraine
  8.3.5 Turkey
8.4 Asia Pacific
  8.4.1 Overview
  8.4.2 India
  8.4.3 Pakistan
  8.4.4 Indonesia
  8.4.5 Thailand
8.5 Rest of the World
  8.5.1 Overview
  8.5.2 Mexico
  8.5.3 Brazil
  8.5.4 Middle East and Africa

9 COMPETITIVE LANDSCAPE

10 VENDORS PROFILE

10.1 AbbVie Inc.
  10.1.1 Overview
  10.1.2 Geographic Revenue
  10.1.3 Business Focus
  10.1.4 SWOT Analysis
  10.1.5 Business Strategies
10.2 Novartis AG
  10.2.1 Overview
  10.2.2 Business Units
  10.2.3 Geographic Revenue
  10.2.4 Business Focus
  10.2.5 SWOT Analysis
  10.2.6 Business Strategies
10.3 Amgen Inc.
  10.3.1 Overview
  10.3.2 Geographic Revenue
  10.3.3 Business Focus
  10.3.4 SWOT Analysis
  10.3.5 Business Strategies
10.4 Johnson & Johnson
  10.4.1 Overview
  10.4.2 Business Units
  10.4.3 Geographic Revenue
  10.4.4 Business Focus
  10.4.5 SWOT Analysis
  10.4.6 Business Strategies
10.5 Celgene Corporation
  10.5.1 Overview
  10.5.2 Geographic Revenue
  10.5.3 Business Focus
  10.5.4 SWOT Analysis
  10.5.5 Business Strategies

11 COMPANIES TO WATCH FOR

11.1 Apogenix
  11.1.1 Overview
11.2 Celltrion Healthcare
  11.2.1 Overview
11.3 Samsung Bioepis Co. Ltd.
  11.3.1 Overview
11.4 3SBio Inc.
  11.4.1 Overview
11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd.
  11.5.1 Overview
Annexure
Abbreviations

LIST OF TABLES

TABLE 1 DRUG CLASS AND THEIR FDA APPROVED INDICATIONS
TABLE 2 GLOBAL TNF ALPHA INHIBITOR MARKET REVENUE, BY PRODUCT, 2018–2025 ($MILLION)
TABLE 3 DRUG OVERVIEW: ADALIMUMAB
TABLE 4 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF ADALIMUMAB APPROVED OR IN DEVELOPMENT
TABLE 5 DRUG OVERVIEW: CERTOLIZUMAB PEGOL
TABLE 6 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF CERTOLIZUMAB PEGOL IN DEVELOPMENT
TABLE 7 DRUG OVERVIEW: ETANERCEPT
TABLE 8 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF ETANERCEPT APPROVED OR IN DEVELOPMENT
TABLE 9 DRUG OVERVIEW: GOLIMUMAB
TABLE 10 DRUG OVERVIEW: INFLIXIMAB
TABLE 11 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF INFLIXIMAB IN DEVELOPMENT
TABLE 12 MOLECULES IN PIPELINE IN PHASE I
TABLE 13 MOLECULES IN PIPELINE IN PHASE II
TABLE 14 MOLECULES IN PIPELINE IN PHASE III
TABLE 15 GLOBAL TNF ALPHA INHIBITORS DRUGS MARKET REVENUE, BY GEOGRAPHY, 2018–2025 ($MILLION)
TABLE 16 ABBVIE INC.: OFFERINGS
TABLE 17 ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 18 NOVARTIS AG: OFFERINGS
TABLE 19 NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 20 AMGEN INC.: OFFERINGS
TABLE 21 AMGEN INC.: RECENT DEVELOPMENTS
TABLE 22 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 23 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 24 CELGENE CORPORATION: OFFERINGS
TABLE 25 CELGENE CORPORATION: RECENT DEVELOPMENTS
TABLE 26 APOGENIX: SNAPSHOT
TABLE 27 APOGENIX: RECENT DEVELOPMENTS
TABLE 28 CELLTRION HEALTHCARE: SNAPSHOT
TABLE 29 CELLTRION HEALTHCARE: RECENT DEVELOPMENTS
TABLE 30 SAMSUNG BIOEPIS CO. LTD.: SNAPSHOT
TABLE 31 SAMSUNG BIOEPIS CO. LTD.: RECENT DEVELOPMENTS
TABLE 32 3SBIO INC.: SNAPSHOT
TABLE 33 3SBIO INC.: RECENT DEVELOPMENTS
TABLE 34 SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTD.: SNAPSHOT

LIST OF FIGURES

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2017)
CHART 2 PHARMACEUTICAL DRUGS BY SALES, 2018
CHART 3 RESEARCH METHODOLOGY OF GLOBAL TNF ALPHA INHIBITORS MARKET
CHART 4 GLOBAL TNF ALPHA INHIBITORS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 5 SEGMENTATION OF GLOBAL TNF ALPHA INHIBITORS MARKET
CHART 6 PEST ANALYSIS OF GLOBAL TNF ALPHA INHIBITORS MARKET
CHART 7 PORTER 5 FORCES ON GLOBAL TNF ALPHA INHIBITORS MARKET
CHART 8 MARKET DYNAMICS – DRO ANALYSIS
CHART 9 DRO – IMPACT ANALYSIS OF GLOBAL TNF ALPHA INHIBITORS MARKET
CHART 10 KEY STAKEHOLDERS
CHART 11 HUMIRA ANNUAL REVENUE, 2011–2018 ($MILLION)
CHART 12 ADALIMUMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 13 PIPELINE ANALYSIS OF ADALIMUMAB
CHART 14 CIMZIA ANNUAL REVENUE, 2011–2018 ($MILLION)
CHART 15 CERTOLIZUMAB PEGOL MARKET REVENUE, 2018–2025 ($MILLION)
CHART 16 PIPELINE ANALYSIS OF CERTOLIZUMAB PEGOL
CHART 17 ETANERCEPT DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 18 PIPELINE ANALYSIS OF ETANERCEPT
CHART 19 GOLIMUMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 20 PIPELINE ANALYSIS OF GOLIMUMAB
CHART 21 INFLIXIMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION)
CHART 22 PIPELINE ANALYSIS OF INFLIXIMAB
CHART 23 GLOBAL TNF ALPHA INHIBITOR DRUGS PIPELINE
CHART 24 MOLECULES IN PHASE I
CHART 25 MOLECULES IN PHASE II
CHART 26 MOLECULES IN PHASE III
CHART 27 GLOBAL TNF ALPHA INHIBITORS DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2018 (%)
CHART 28 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION)
CHART 29 ADALIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 30 ADALIMUMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 31 CERTOLIZUMAB PEGOL NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 32 CERTOLIZUMAB PEGOL NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 33 ETANERCEPT NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 34 ETANERCEPT NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 35 GOLIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 36 GOLIMUMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 37 INFLIXIMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 38 INFLIXIMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 39 ADALIMUMAB MARKET REVENUE IN US, 2018–2025 ($MILLION)
CHART 40 CERTOLIZUMAB PEGOL MARKET REVENUE IN US, 2018–2025 ($MILLION)
CHART 41 ETANERCEPT MARKET REVENUE IN US, 2018–2025 ($MILLION)
CHART 42 GOLIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 43 INFLIXIMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION)
CHART 44 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION)
CHART 45 ADALIMUMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION)
CHART 46 ADALIMUMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 47 CERTOLIZUMAB PEGOL EUROPE MARKET REVENUE, 2018–2025 ($MILLION)
CHART 48 CERTOLIZUMAB PEGOL EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 49 ETANERCEPT EUROPE MARKET REVENUE, 2018–2025 ($MILLION)
CHART 50 ETANERCEPT EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 51 GOLIMUMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION)
CHART 52 GOLIMUMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 53 INFLIXIMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION)
CHART 54 INFLIXIMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 55 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION)
CHART 56 ADALIMUMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION)
CHART 57 ADALIMUMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 58 CERTOLIZUMAB PEGOL ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION)
CHART 59 CERTOLIZUMAB PEGOL ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 60 ETANERCEPT ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION)
CHART 61 ETANERCEPT ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 62 GOLIMUMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION)
CHART 63 GOLIMUMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 64 INFLIXIMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION)
CHART 65 INFLIXIMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 66 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION)
CHART 67 ADALIMUMAB ROW MARKET REVENUE, 2018–2025 ($MILLION)
CHART 68 ADALIMUMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 69 CERTOLIZUMAB PEGOL ROW MARKET REVENUE, 2018–2025 ($MILLION)
CHART 70 CERTOLIZUMAB PEGOL ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 71 ETANERCEPT ROW MARKET REVENUE, 2018–2025 ($MILLION)
CHART 72 ETANERCEPT ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 73 GOLIMUMAB ROW MARKET REVENUE, 2018–2025 ($MILLION)
CHART 74 GOLIMUMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 75 INFLIXIMAB ROW MARKET REVENUE, 2018–2025 ($MILLION)
CHART 76 INFLIXIMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE)
CHART 77 ANNUAL TREATMENT COST
CHART 78 ABBVIE INC.: OVERVIEW SNAPSHOT
CHART 79 ABBVIE INC.: GEOGRAPHIC REVENUE
CHART 80 ABBVIE INC.: SWOT ANALYSIS
CHART 81 NOVARTIS AG: OVERVIEW SNAPSHOT
CHART 82 NOVARTIS AG: BUSINESS UNITS
CHART 83 NOVARTIS AG: GEOGRAPHIC REVENUE
CHART 84 NOVARTIS AG: SWOT ANALYSIS
CHART 85 AMGEN INC.: OVERVIEW SNAPSHOT
CHART 86 AMGEN INC.: GEOGRAPHIC REVENUE
CHART 87 AMGEN INC.: SWOT ANALYSIS
CHART 88 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 89 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 90 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 91 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 92 CELGENE CORPORATION: OVERVIEW SNAPSHOT
CHART 93 CELGENE CORPORATION: GEOGRAPHIC REVENUE
CHART 94 CELGENE CORPORATION: SWOT ANALYSIS


More Publications